Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Where to Put $1,000 In 2021

By Howard Smith - Jan 5, 2021 at 6:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These two cannabis stocks have risk, but they also have growing sales.

Investors need a diversified portfolio, but not everyone has the tolerance for including risky, speculative stocks in the mix. But for those who do, the cannabis sector is one that has shaken off the initial exuberance that came with the legalization of recreational marijuana in Canada in 2018 and still offers interesting long-term opportunities.

Some companies are continuing to grow with the budding market, and others have overspent building infrastructure -- perhaps because they thought U.S. legalization would have arrived already. If you have $1,000 to invest in 2021 and still want to bet on the eventual federal legalization in the U.S., two stocks worth a look are Aphria ( APHA ) and EnWave ( NWVCF -0.10% )

Workers in shed with drying cannabis plants

Image source: Getty Images.

Strategizing for the future

Marijuana grower and distributor Aphria has been busy recently. In early November, it announced it would spend $300 million to buy U.S. craft brewer SweetWater Brewing Company. Not only will this acquisition be immediately accretive to earnings before interest, taxes, depreciation, and amortization (EBITDA) and diluted earnings per share, but there is also a clear cultural and product fit. In 2018, SweetWater released a hemp-strain IPA called 420 Strain G13, which earned the title of top craft brand in the U.S. in its first 12 months on the market.

SweetWater has a growing business. For the year ended Dec. 31, 2019, the company reported revenue of $67 million, adjusted EBITDA of $22 million, and a growth rate of twice the national craft beer market, according to the announcement. But Aphria's strategy isn't for short-term income here. It's for the growing U.S.-based market. SweetWater is currently available in 27 states plus the District of Columbia, and Aphria said that it provides "a platform and infrastructure within the U.S. to enable it to access the U.S. market more quickly in the event of federal legalization."

Aphria's next strategic move was to merge with fellow Canadian cannabis grower Tilray ( TLRY ). Aphria shareholders will own about 62% of the newly combined company, should it be finalized. It will continue under the Tilray name, but be led by Aphria chairman and CEO Irwin Simon. The combination will make it the largest current global cannabis company in terms of revenue.

These moves come at a time of growing sales, and a lower share price, as can be seen in this three-year chart. 

APHA Chart

APHA data by YCharts

Technology for the growers

EnWave offers growers a patented dehydration technology to replace freeze drying or air drying for a faster, high-quality drying process. This efficiency allows growers to increase production, which will increase sales when demand is sufficient. 

The low temperature Radiant Energy Vacuum (REV) dehydration system is also used in food and pharmaceutical applications. So EnWave isn't completely counting on the cannabis industry for revenue, but the most dramatic investment thesis for this small-cap company depends on it. 

EnWave's current business is dominated by its NutraDried Moon Cheese dried-cheese snack product, which can be ordered online or found in retail grocery chains. NutraDried sales represented more than 80% of revenue in the last two quarters.

The company signed 10 new royalty-bearing license agreements and sold 11 10-kilowatt (kW) REV machines in 2020. It also offers larger 60kW and 100kW machines. For investors, now is the time to look at EnWave, as it appears to be at an inflection point in its growth. In its latest earnings release, EnWave management said: "Our strategies have shifted away from preservation and we have returned to aggressively pursuing growth."

Speculation as an investment

Some investors who have $1,000 to invest in 2021 don't want to speculate, and shouldn't. But if you have the risk tolerance, and are able to risk that money, these two cannabis stocks seem to be at a good place in their life cycles to invest. 

Speculation implies a chance of seeing outsized gains, with the risk of a total capital loss. That type of investment isn't for everyone. Besides, federal legalization of marijuana in the U.S. will be the key to seeing both of these companies soar. And there's no guarantee of that, even if the Senate tips in Democrat's favor after Georgia run-off elections today.

Aphria and EnWave have businesses that will survive without that catalyst -- but to truly wring the full potential out of these stocks, investors must accept that there is political risk that might either take a long time to pan out, or may not pan out at all. But that's part of what high-risk investments entail. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aphria Stock Quote
Tilray Stock Quote
EnWave Stock Quote
$0.71 (-0.10%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.